Updates on second-generation laser intravascular lithotripsy (IVL) technology to treat above the knee stenotic lesions, 90% of which were severely calcified, show good efficacy and safety outcomes with no distal embolisation and no dissections.

Dr Marianne Brodmann (Medical University of Graz, Graz, AT) joins us to discuss updates from the prospective, non-randomized, first-in-human RESTORE ATK trial (NCT05662787; Bolt Medical), investigating the efficacy and safety of the Bolt IVL System in patients with above the knee stenotic lesions classified as Rutherford category 2 to 4.

Interview Questions:
1. What is the background behind the RESTORE ATK trial?
2. Could you tell us about the unique features of the Bolt IVL System?
3. What was the study design and patient population?
4. What were the key findings?
5. How should these findings impact clinical practice?
6. What further study is needed in this area?

Recorded remotely from Graz, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh and Oliver Miles

Support: This is an independent interview produced by Radcliffe Vascular.